STARLiT

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Jan 15, 2025 → Sep 30, 2026

Cited window

Jan 15, 2025 → Sep 30, 2025

Retrieved

Oct 30, 2026

Title

STARLiT: STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer: A Phase I/II Trial

Registry

NCT06574880

Study IDs

CASE7824

Sponsor

Angela Y. Jia, MD PhD

Design

Phase 1/Phase 2 · Interventional, single group

Status

Recruiting

Enrollment

45 estimated

Registered

2024-08-28

Start

2025-05-13 actual

Primary completion

2026-09-01 estimated

Primary endpoint

Phase I: Maximum tolerated dose (MTD) of Lu-PSMA-617

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –43 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits apply, so some matching discussion may be missing.
• –The sources reviewed for this edition do not represent all HCPs or all public discussion; additional relevant views may be absent.
• –Some short passages were not fully assessed, and one additional potentially relevant source was not read. References that do not name the trial or use different wording may also be missing.
• –No full study protocol or exact-trial results publication was identified. Registry methods and presentation objectives cannot establish observed treatment benefit or safety.
• –The available material does not establish regulatory authorization for this use.
• –The trial-unnamed February X exchange does not establish which study supplied its safety data or whether its advanced-disease discussion matches STARLiT's population.
• –Local practice, access restrictions and adoption forecasts reflect their source timing and settings; they should not be read as current or universal policies.
• –A speaker's principal-investigator involvement and the presenter's involvement are descriptions made by the sources, not independently established trial roles.
• –Not yet captured in this edition: a question about future integration and universal adoption of SBRT and PSMA PET.
• –Not yet captured in this edition: a view on biological testing to identify patients most likely to benefit from treatment.

How reports are built and checked: Methods.

Last checked for new commentary Oct 30, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "STARLiT" (NCT06574880), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "starlit-06574880". If you cannot make requests, read https://www.erudio.com/reports/starlit-nct06574880.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06574880", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06574880 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/starlit-nct06574880.json
curl https://www.erudio.com/reports/starlit-nct06574880.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "starlit-06574880" })